June 20, 2023: In our public comment, NCHR agrees with USPSTF that there is insufficient evidence to recommend routine oral health screening of adults by primary care clinicians. We urged that new research be conducted to determine the benefits and harms of screening, primary care counseling, dental referral, and oral health preventive interventions administered in primary care settings for adults.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Comments on USPSTF Draft Recommendation for Oral Health in Children and Adolescents
June 20, 2023: In our public comment, NCHR agrees with USPSTF that there is insufficient evidence to recommend routine oral health screening by primary care clinicians in children ages 5 to 17 years. Available research evidence is limited to studies assessing oral health preventive interventions that were administered by dental professionals or in supervised school settings, but not in primary care settings. We strongly recommend that well-designed research be conducted to fill these gaps.
Read More »NCHR Testimony at the FDA Oncologic Drugs Advisory Committee Meeting on Pediatric Dosage for Cancer Drugs, June 16, 2023
June 16, 2023: NCHR testified on how to choose dosages for pediatric cancer drugs, stating that variables such as weight, age, sex, race, and organ impairment should be studied to identify differences in safety or effectiveness for subpopulations. We also strongly support the specifications about drug safety and tolerability, requiring factors such as duration of exposure and adverse events to be compared across varying dosages.
Read More »NCHR Comments on EPA Greenhouse Gas Emission Standards for Heavy-Duty Vehicles
June 16, 2023: NCHR responds to EPA’s request for public comments on the new emission standards for heavy-duty vehicles. We strongly urge the EPA to strengthen the proposed standards by requiring 100% zero-emission sales by 2035 in the final rule to protect public health and set the United States on a path to a zero-emissions future.
Read More »NCHR Comment on USPSTF Draft Research Plan on Weight Loss Intervention
June 14, 2023: Obesity affects nearly half of US adults (42%) and is extremely costly to the US healthcare system, costing $173 billion in 2019. We responded to USPSTF’s request for public comments regarding their research plan, which is aimed at evaluating which pharmaceutical and behavioral treatments for obesity are proven to improve the health of adults, as well as any risks associated with those interventions.
Read More »